PHASEBIO PHARMACEUTICALS

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PHASQ and buy or sell other stocks, ETFs, and their options commission-free!

About PHASQ

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. 

CEO
Jonathan P. Mow, MBA
CEOJonathan P. Mow, MBA
Employees
Employees
Headquarters
Dover, Delaware
HeadquartersDover, Delaware
Founded
2002
Founded2002
Employees
Employees

PHASQ Key Statistics

Market cap
Market cap
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.40
Average volume1.40
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.001
52 Week high$0.001
52 Week low
52 Week low

Stock Snapshot

As of today, PHASEBIO PHARMACEUTICALS(PHASQ) shares are valued at $0.00.

During the trading day, PHASEBIO PHARMACEUTICALS(PHASQ) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.4.

People also own

Based on the portfolios of people who own PHASQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.